Ghrelin effects expression of several genes associated with depression-like behavior

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 56, Issue , 2015, Pages 227-234

  Poretti, María Belén ^a   Rask Andersen, Mathias ^b   Kumar, Praveen ^b   Rubiales de Barioglio, Susana ^c   Fiol de Cuneo, Marta ^a   Schiöth, Helgi B ^b   Carlini, Valeria Paola ^a  

^a FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

^b UPPSALA UNIVERSITY   (Sweden)

^c UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

Author keywords

Corticotrophin releasing hormone; Ghrelin; Olfactory bulbectomy; Opioid receptors; Vasopressin

Indexed keywords

CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; DELTA OPIATE RECEPTOR; GHRELIN; INTERLEUKIN 1BETA; KAPPA OPIATE RECEPTOR; MU OPIATE RECEPTOR; SEROTONIN TRANSPORTER; VASOPRESSIN; ANTIDEPRESSANT AGENT; ARGIPRESSIN; IL1B PROTEIN, MOUSE; LUTEINIZING HORMONE RECEPTOR; OPIATE RECEPTOR;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORTICOTROPHIN RELEASING HORMONE GENE; CORTICOTROPIN BLOOD LEVEL; DELTA OPIOID RECEPTOR GENE; DEPRESSION; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; INTERLEUKIN 1 BETA RECEPTOR GENE; KAPPA OPIOID RECEPTOR GENE; LUTROPIN CHORIOGONADOTROPIC HORMONE RECEPTOR GENE; MOUSE; MU OPIOID RECEPTOR GENE; NONHUMAN; OLFACTORY BULBECTOMY; SEROTONIN TRANSPORTER GENE; VASOPRESSIN BLOOD LEVEL; VASOPRESSIN GENE; ANALYSIS OF VARIANCE; ANIMAL; BLOOD; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; INJURIES; METABOLISM; OLFACTORY BULB;

ADRENOCORTICOTROPIC HORMONE; ANALYSIS OF VARIANCE; ANIMALS; ANTIDEPRESSIVE AGENTS; ARGININE VASOPRESSIN; CORTICOTROPIN-RELEASING HORMONE; DEPRESSION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION; GHRELIN; INTERLEUKIN-1BETA; MICE; OLFACTORY BULB; RECEPTORS, LH; RECEPTORS, OPIOID; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 84908178906     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2014.09.012     Document Type: Article

References (68)

1. Asakawa A., Inui A., Kaga T., Yuzuriha H., Nagata T., Fujimiya M., et al. A role of ghrelin in neuroendocrine and behavioral responses to stress in mice. Neuroendocrinology 2001, 74:143-147.
2. Barden N. Implication of the hypothalamic-pituitary-adrenal axis in the physiopathology of depression. J Psychiatry Neurosci 2004, 185-193.
3. Bartolomucci A., Carola V., Pascucci T., Puglisi-Allegra S., Cabib S., Lesch K.P., et al. Increased vulnerability to psychosocial stress in heterozygous serotonin transporter knockout mice. Dis Model Mech 2010, 3(7-8):459-470.
4. Bodnar R.J., Klein G.E. Endogenous opiates and behavior: 2003. Peptides 2004, 25:2205-2206.
5. Broekkamp C.L., O'Connor W.T., Tonnaer J.A., Rijk H.W., Van Delft A.M. Corticosterone, choline acetyltransferase and norepinephrine levels in olfactory bulbectomized rats in relation to changes in passive avoidance acquisition and open field activity. Physiol Behav. 1986, 37:429-434.
6. Broom D.C., Jutkiewicz E.M., Rice K.C., Traynor J.R., Woods J.H. Behavioral effects of δ-opioid receptor agonists: potential antidepressants?. Jpn J Pharmacol 2002, 90:1-6.
7. Brunetti L., Recinella L., Orlando G., Michelotto B., Di Nisio C., Vacca M. Effects of ghrelin and amylin on dopamine, norepinephrine and serotonin release in the hypothalamus. Eur J Pharmacol 2002, 454(2-3):189-192.
8. Carlini V.P., Monzon M.E., Varas M.M., Cragnolini A.B., Schioth H.B., Scimonelli T.N., et al. Ghrelin increases anxiety-like behavior and memory retention in rats. Biochem Biophys Res Commun 2002, 299:739-743.
9. Carlini V.P., Varas M.M., Cragnolini A.B., Schioth H.B., Scimonelli T.N., de Barioglio S.R. Differential role of the hippocampus, amygdala, and dorsal raphe nucleus in regulating feeding, memory, and anxiety-like behavioral responses to ghrelin. Biochem Biophys Res Commun 2004, 313:635-641.
10. Carlini V.P., Martini A.C., Schiöth H.B., Ruiz R.D., Fiol de Cuneo M., de Barioglio S.R. Decreased memory for novel object recognition in chronically food-restricted mice is reversed by acute ghrelin administration. Neuroscience 2008, 153(4):929-934.
11. Carlini V.P., Machado D.G., Buteler F., Ghersi M., Ponzio M.F., Martini A.C., et al. Acute ghrelin administration reverses depressive-like behavior induced by bilateral olfactory bulbectomy in mice. Peptides 2012, 35:160-165.
12. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008, 9:46-57.
13. Delporte C. Structure and physiological actions of ghrelin. Scientifica (Cairo) 2013, 13:518909. [Review].
14. Douma S.L., Husband C., O'Donnell M.E., Barwin B.N., Woodend A.K. Estrogen-related mood disorders: reproductive life cycle factors. ANS Adv Nurs Sci 2005, 28(4):364-375. [Review].
15. Dowlati Y., Herrmann N., Swardfager W., Liu H., Sham L., Reim E.K., et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010, 67:446-457.
16. Franklin K., Paxinos G. The mouse brain in stereotaxic coordinates 2008, Elsevier/Academic Press. 3rd ed.
17. Ghersi M.S., Casas S.M., Escudero C., Carlini V.P., Buteler F., Cabrera R.J., et al. Ghrelin inhibited serotonin release from hippocampal slices. Peptides 2011, 32(11):2367-2371.
18. Haddley K., Vasiliou A.S., Ali F.R., Paredes U.M., Bubb V.J., Quinn J.P. Molecular genetics of monoamine transporters: relevance to brain disorders. Neurochem Res 2008, 33:652-667.
19. Hansson C., Haage D., Taube M., Egecioglu E., Salome N., Dickson S.L. Central administration of ghrelin alters emotional responses in rats: behavioural, electrophysiological and molecular evidence. Neuroscience 2011, 180:201-211.
20. Hansson C., Alvarez-Crespo M., Taube M., Skibicka K.P., Schmidt L., Karlsson-Lindahl L., et al. Influence of ghrelin on the central serotonergic signaling system in mice. Neuropharmacology 2014, 79:498-505.
21. Hayley S., Poulter M.O., Merali Z., Anisman H. The pathogenesis of clinical depression: stressor- and cytokine-induced alterations of neuroplasticity. Neuroscience 2005, 135(3):659-678. [Review].
22. Heilig M. The NPY, system in stress, anxiety and depression. Neuropeptides 2004, 38:213-224.
23. Hepgul N., Cattaneo A., Zunszain P.A., Pariante C.M. Depression pathogenesis and treatment: what can we learn from blood mRNA expression?. BMC Med 2013, 11:28.
24. Holmes A., Yang R.J., Murphy D.L., Crawley J.N. Evaluation of antidepressant-related behavioral responses in mice lacking the serotonin transporter. Neuropsychopharmacology 2002, 27(6):914-923.
25. Holmes A., Lit Q., Murphy D.L., Gold E., Crawley J.N. Abnormal anxiety-related behavior in serotonin transporter null mutant mice: the influence of genetic background. Genes Brain Behav 2003, 2(6):365-380.
26. Holsboer F., Barden N. Antidepressants and hypothalamic-pituitary-adrenocortical regulation. Endocr Rev 1996, 187-205.
27. Howard A.D., Feighner S.D., Cully D.F., Arena J.P., Liberator P.A., Rosenblum C.I., et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 1996, 273(5277):974-977.
28. Howren M.B., Lamkin D.M., Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 2009, 71:171-186.
29. Huether G., Zhou D., Ruther E. Long-term modulation of presynaptic 5-HT-output: Experimentally induced changes in cortical 5-HT-transporter density, tryptophan hydroxylase content and 5-HT innervation density. Journal of Neural Transmission General Section 1997, 104:993-1004.
30. Jancsár S.M., Leonard B.E. The effect of (+/-)mianserin and its enantiomers on the behavioural hyperactivity of the olfactory-bulbectomized rat. Neuropharmacology. 1984, 23:1065-1070.
31. Kanehisa M., Akiyoshi J., Kitaichi T., Matsushita H., Tanaka E., Kodama K., et al. Administration of antisense DNA for ghrelin causes an antidepressant and anxiolytic response in rats. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:1403-1407.
32. Korbonits M., Grossman A.B. Ghrelin: update on a novel hormonal system. Eur J Endocrinol 2004, 151(Suppl. 1):S67-S70.
33. Kurt E., Guler O., Serteser M., Cansel N., Ozbulut O., Altinbaş K., et al. The effects of electroconvulsive therapy on ghrelin, leptin and cholesterol levels in patients with mood disorders. Neurosci Lett 2007, 426:49-53.
34. Leonard B., Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev 2012, 36(2):764-785. [Review].
35. Li Q., Wichems C., Heils A., Van De Kar L.D., Lesch K.P., Murphy D.L. Reduction of 5-hydroxytryptamine (5-HT)(1A)-mediated temperature and neuroendocrine responses and 5-HT(1A) binding sites in 5-HT transporter knockout mice. J Pharmacol Exp Ther 1999, 291(3):999-1007.
36. Li K., Zhou T., Liao L., Yang Z., Wong C., Henn F., et al. βCaMKII in lateral habenula mediates core symptoms of depression. Science 2013, 341(6149):1016-1020.
37. Lutter M., Sakata I., Osborne-Lawrence S., Rovinsky S.A., Anderson J.G., Jung S., et al. The orexigenic hormone ghrelin defends against depressive symptoms of chronic stress. Nat Neurosci 2008, 11:752-753.
38. Maes M. Cytokines in major depression. Biol Psychiatry 1994, 36:498-499.
39. Marcilhac A., Anglade G., Hery F., Siaud P. Olfactory bulbectomy increases vasopressin, but not corticotropin-releasing hormone, content in the external layer of the median eminence of male rats. Neurosci Lett 1999, 262:89-92.
40. Miller A.H., Maletic V., Raison C.L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009, 65:732-741.
41. Molteni R., Macchi F., Riva M.A. Gene expression profiling as functional readout of rodent models for psychiatric disorders. Cell Tissue Res 2013, 354:51-60.
42. Mozid A.M., Tringali G., Forsling M.L., Hendricks M.S., Ajodha S., Edwards R., et al. Ghrelin is released from rat hypothalamic explants and stimulates corticotrophin-releasing hormone and arginine-vasopressin. Horm Metab Res 2003, 35(8):455-459.
43. Nakashima K., Akiyoshi J., Hatano K., Hanada H., Tanaka Y., Tsuru J., et al. Ghrelin gene polymorphism is associated with depression, but not panic disorder. Psychiatr Genet 2008, 18:257.
44. Nemeroff C.B., Widerlov E., Bissette G., Walleus H., Karlsson I., Eklund K., et al. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 1984, 226:1342-1344.
45. Niitsu T., Fabbri C., Bentini F., Serreti A. Pharmacogenetics in major depression: a comprehensive meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 2013, 45:183-194.
46. Nonkes L.J., Tomson K., Maertin A., Dederen J., Maes J.H., Homberg J. Orbitofrontal cortex and amygdalar over-activity is associated with an inability to use the value of expected outcomes to guide behaviour in serotonin transporter knockout rats. Neurobiol Learn Mem 2010, 94(1):65-72.
47. Olivier J.D., Van Der Hart M.G., Van Swelm R.P., Dederen P.J., Homberg J.R., Cremers T., et al. A study in male and female 5-HT transporter knockout rats: an animal model for anxiety and depression disorders. Neuroscience 2008, 152(3):573-584.
48. Patterson Z.R., Ducharme R., Anisman H., Abizaid A. Altered metabolic and neurochemical responses to chronic unpredictable stressors in ghrelin receptor-deficient mice. Eur J Neurosci 2010, 32:632-639.
49. Perrine S.A., Hoshaw B.A., Unterwald E.M. Delta opioid receptor ligands modulate anxiety-like behaviors in the rat. Br J Pharmacol 2006, 147(8):864-872.
50. Raadsheer F.C., Hoogendijk W.J., Stam F.C., Tilders F.J., Swaab D.F. Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology 1994, 60:436-444.
51. Redrobe J.P., Dumont Y., Fournier A., Quirion R. The neuropeptide Y (NPY) Y1 receptor subtype mediates NPY-induced antidepressant-like activity in the mouse forced swimming test. Neuropsychopharmacology 2002, 26:615-624.
52. Rivier C., Rivest S. Effect of stress on the activity of the hypothalamic-pituitary-gonadal axis: peripheral and central mechanisms. Biol Reprod 1991, 45(4):523-532. [Review].
53. Schmid D.A., Wichniak A., Uhr M., Ising M., Brunner H., Held K., et al. Changes of sleep architecture, spectral composition of sleep EEG, the nocturnal secretion of cortisol, ACTH, GH, prolactin, melatonin, ghrelin, and leptin, and the DEX-CRH test in depressed patients during treatment with mirtazapine. Neuropsychopharmacology 2006, 31:832-844.
54. Scott L.V., Dinan T.G. Vasopressin and the regulation of hypothalamic-pituitary-adrenal axis function: implications for the pathophysiology of depression. Life Sci 1998, 1985-1998.
55. Shelton R.C., Claiborne J., Sidoryk-Wegrzynowicz M., Reddy R., Aschner M., Lewis D.A., et al. Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression. Mol Psychiatry 2011, 16:751-762.
56. Skibicka K.P., Shirazi R.H., Hansson C., Dickson S.L. Ghrelin interacts with neuropeptide Y Y1 and opioid receptors to increase food reward. Endocrinology 2012, 153(3):1194-1205.
57. Smith S.M., Vale W.W. The role of the hypothalamic-pituitary-adrenal axis in neuroendocrine responses to stress. Dialogues Clin Neurosci 2006, 8:383-395.
58. Song C., Leonard B.E. Interleukin-2-induced changes in behavioural, neurotransmitter, and immunological parameters in the olfactory bulbectomized rat. Neuroimmunomodulation 1995, 2(5):263-273.
59. Spencer S.J., Xu L., Clarke M.A., Lemus M., Reichenbach A., Geenen B., et al. Ghrelin regulates the hypothalamic-pituitary-adrenal axis and restricts anxiety after acute stress. Biol Psychiatry 2012, 72(6):457-465. [15].
60. Stogner K.A., Holmes P.V. Neuropeptide-Y exerts antidepressant-like effects in the forced swim test in rats. Eur J Pharmacol 2000, 387:9-10.
61. Tejedor-Real P., Micó J.A., Smadja C., Maldonado R., Roques B.P., Gilbert-Rahola J. Involvement of delta-opioid receptors in the effects induced by endogenous enkephalins on learned helplessness model. Eur J Pharmacol 1998, 354(1):1-7.
62. Tjurmina O.A., Armando I., Saavedra J.M., Goldstein D.S., Murphy D.L. Exaggerated adrenomedullary response to immobilization in mice with targeted disruption of the serotonin transporter gene. Endocrinology 2002, 143(12):4520-4526.
63. Torregrossa M.M., Jutkiewicz E.M., Mosberg H.I., Balboni G., Watson S.J., Woods J.H. Peptidic delta opioid receptor agonists produce antidepressant-like effects in the forced swim test and regulate BDNF mRNA expression in rats. Brain Res 2006, 1069(1):172-181.
64. Tsao C.W., Lin Y.S., Chen C.C., Bai C.H., Wu S.R. Cytokines and serotonin transporter in patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30(5):899-905.
65. van Riezen H., Leonard B.E. Effects of psychotropic drugs on the behavior and neurochemistry of olfactory bulbectomized rats. Pharmacol Ther. 1990, 47:21-34.
66. Vandesompele J., De Preter K., Pattyn F., Poppe B., Van Roy N., De Paepe A., et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002, 3(7). [18, RESEARCH0034].
67. Waseem T., Duxbury M., Ito H., Ashley S.W., Robinson M.K. Exogenous ghrelin modulates release of pro-inflammatory and anti-inflammatory cytokines in LPS-stimulated macrophages through distinct signaling pathways. Surgery 2008, 143(3):334-342.
68. Zhou D., Grecksch G., Becker A., Frank C., Pilz J., Huether G. Serotonergic hyperinnervation of the frontal cortex in an animal model of depression, the bulbectomized rat. J Neurosci Res. 1998, 54:109-116.